aod9604 igf-1 levels The effects of a 14 day infusion of saline (control), or hGH on aod9604 igf 1 levels study

The compound has been studied across multiple research streams covering its mechanism, biological-activity profile, and translational-research framings

Related products can be reviewed in the COA Verified Research Peptides collection

Dosage and frequency of injections can influence overall costs as well

Side Effects & Safety AOD-9604 has a favorable safety profile supported by clinical trial data: FDA GRAS status: The compound received GRAS status as a food ingredient, reflecting some regulatory safety evaluation, though this is not equivalent to drug safety approval Clinical trial tolerability: Phase I and Phase II clinical trials conducted by Metabolic Pharmaceuticals generally found AOD-9604 well-tolerated at studied doses Injection site reactions: Minor discomfort with subcutaneous administration Headache and nausea: Reported in some clinical trial subjects No significant metabolic effects: Blood glucose, insulin, HbA1c, and IGF-1 were not significantly altered in clinical studies, which distinguishes it favorably from full GH Long-term safety data for subcutaneous use in the research community context (typically higher and more frequent dosing than clinical trials) is limited